CSR Program: IAEA | Takeda Pharmaceuticals
Enhancing national laboratories’ diagnostic capabilities
Testing can be available when and where people need it
The Program
Partner: International Atomic Energy Agency (IAEA)
Budget: 500 million yen
Term: COVID-19 Emergency Response
Launch: 2020
Area: Worldwide
Visit the IAEA website
Over 280 national-designated laboratories for COVID-19 in 127 countries and territories around the world have requested and are receiving the Agency’s assistance and demand is still increasing. The IAEA - Takeda partnership helps the IAEA to continue providing emergency assistance in the form of diagnostic kits, equipment and technical advice and guidance to help rapidly and accurately detect and identify the novel coronavirus that causes COVID-19.
IAEA’s emergency assistance package includes a real-time RT-PCR diagnostic machine, biosafety cabinets and equipment for sampling, testing, quality control as well as personal protection to run 2,000 tests. Additional support refers to the guidance and provision of standard operating procedures to identify the virus, following the World Health Organization recommendations.
Photo Credit: Central Laboratories, Ministry of Health, Jordan
Photo Credit: C. Orellana Vaquero / Chile
Stories of Impact
Enhancing national laboratories’ diagnostic capabilities for COVID-19
A total of 98,000 people were reached through our partnership with IAEA to build diagnostic capabilities through equipment and technical guidance and training to help national-designated laboratories and institutions detect and identify the novel coronavirus that causes COVID-19. The partnership came to a close in 2021.
Photo Credit: C. Madara / Kenya
See how Takeda's partnership with IAEA is helping 49 laboratories in 37 countries reach 98,000 people with safe, reliable, and rapid COVID-19 diagnosis and critical safety, testing, and quality control equipment in this video.
Have more questions?
Contact us if you'd like more information about our Global CSR Program.